6V12
 
 | | Empty AAV8 particles | | Descriptor: | Capsid protein | | Authors: | Mietzsch, M, Agbandje-McKenna, M. | | Deposit date: | 2019-11-19 | | Release date: | 2019-12-11 | | Last modified: | 2024-03-06 | | Method: | ELECTRON MICROSCOPY (3.08 Å) | | Cite: | Comparative Analysis of the Capsid Structures of AAVrh.10, AAVrh.39, and AAV8.
J.Virol., 94, 2020
|
|
6B9Q
 | |
6V10
 | | genome-containing AAV8 particles | | Descriptor: | Capsid protein, DNA (5'-D(*CP*A)-3') | | Authors: | Mietzsch, M, Agbandje-McKenna, M. | | Deposit date: | 2019-11-19 | | Release date: | 2019-12-11 | | Last modified: | 2024-06-12 | | Method: | ELECTRON MICROSCOPY (3.77 Å) | | Cite: | Comparative Analysis of the Capsid Structures of AAVrh.10, AAVrh.39, and AAV8.
J.Virol., 94, 2020
|
|
7YSE
 | | Crystal structure of E. coli heterotetrameric GlyRS in complex with tRNA | | Descriptor: | Glycine--tRNA ligase alpha subunit, Glycine--tRNA ligase beta subunit, MAGNESIUM ION, ... | | Authors: | Han, L, Ju, Y, Zhou, H. | | Deposit date: | 2022-08-12 | | Release date: | 2023-02-01 | | Last modified: | 2023-11-29 | | Method: | X-RAY DIFFRACTION (2.907 Å) | | Cite: | The binding mode of orphan glycyl-tRNA synthetase with tRNA supports the synthetase classification and reveals large domain movements.
Sci Adv, 9, 2023
|
|
6V1G
 | | Genome-containing AAVrh.10 | | Descriptor: | Capsid protein VP1, DNA (5'-D(*CP*A)-3') | | Authors: | Mietzsch, M, Agbandje-McKenna, M. | | Deposit date: | 2019-11-20 | | Release date: | 2019-12-11 | | Last modified: | 2024-06-12 | | Method: | ELECTRON MICROSCOPY (2.98 Å) | | Cite: | Comparative Analysis of the Capsid Structures of AAVrh.10, AAVrh.39, and AAV8.
J.Virol., 94, 2020
|
|
6V1T
 | | Empty AAVrh.39 particle | | Descriptor: | Capsid protein VP1 | | Authors: | Mietzsch, M, Agbandje-McKenna, M. | | Deposit date: | 2019-11-21 | | Release date: | 2019-12-11 | | Last modified: | 2024-03-06 | | Method: | ELECTRON MICROSCOPY (3.39 Å) | | Cite: | Comparative Analysis of the Capsid Structures of AAVrh.10, AAVrh.39, and AAV8.
J.Virol., 94, 2020
|
|
6VYH
 | | Cryo-EM structure of SLC40/ferroportin in complex with Fab | | Descriptor: | 11F9 heavy-chain, 11F9 light-chain, COBALT (II) ION, ... | | Authors: | Shen, J, Ren, Z, Pan, Y, Gao, S, Yan, N, Zhou, M. | | Deposit date: | 2020-02-26 | | Release date: | 2020-11-11 | | Last modified: | 2022-09-28 | | Method: | ELECTRON MICROSCOPY (3 Å) | | Cite: | Structural basis of ion transport and inhibition in ferroportin.
Nat Commun, 11, 2020
|
|
1I7Z
 | | ANTIBODY GNC92H2 BOUND TO LIGAND | | Descriptor: | CHIMERA OF IG GAMMA-1 CHAIN: HUMAN CONSTANT REGION AND MOUSE VARIABLE REGION, CHIMERA OF IG KAPPA CHAIN: HUMAN CONSTANT REGION AND MOUSE VARIABLE REGION, COCAINE | | Authors: | Larsen, N.A, Wilson, I.A. | | Deposit date: | 2001-03-12 | | Release date: | 2001-08-08 | | Last modified: | 2023-08-09 | | Method: | X-RAY DIFFRACTION (2.3 Å) | | Cite: | Crystal structure of a cocaine-binding antibody.
J.Mol.Biol., 311, 2001
|
|
6WIK
 | | Cryo-EM structure of SLC40/ferroportin with Fab in the presence of hepcidin | | Descriptor: | 11F9 Fab heavy-chain, 11F9 Fab light-chain, Solute carrier family 40 protein | | Authors: | Shen, J, Ren, Z, Pan, Y, Gao, S, Yan, N, Zhou, M. | | Deposit date: | 2020-04-10 | | Release date: | 2020-11-11 | | Last modified: | 2022-08-31 | | Method: | ELECTRON MICROSCOPY (3.4 Å) | | Cite: | Structural basis of ion transport and inhibition in ferroportin.
Nat Commun, 11, 2020
|
|
6X2I
 | |
6WFU
 | |
3ERS
 | | Crystal Structure of E. coli Trbp111 | | Descriptor: | tRNA-binding protein ygjH | | Authors: | Swairjo, M.A. | | Deposit date: | 2008-10-03 | | Release date: | 2008-12-02 | | Last modified: | 2023-12-27 | | Method: | X-RAY DIFFRACTION (1.87 Å) | | Cite: | Crystal structure of Trbp111: a tructure specific tRNA binding protein
Embo J., 19, 2000
|
|
4O04
 | | Identification of novel HSP90/isoform selective inhibitors using structure-based drug design. Demonstration of potential utility in treating CNS disorders such as Huntington's disease | | Descriptor: | 4-(2,7,7-trimethyl-5-oxo-1,2,3,4,5,6,7,8-octahydro-9H-beta-carbolin-9-yl)benzamide, Heat shock protein HSP 90-alpha | | Authors: | Zuccola, H.J, Ernst, J. | | Deposit date: | 2013-12-13 | | Release date: | 2014-12-24 | | Last modified: | 2024-02-28 | | Method: | X-RAY DIFFRACTION (1.82 Å) | | Cite: | Identification of Novel HSP90 alpha / beta Isoform Selective Inhibitors Using Structure-Based Drug Design. Demonstration of Potential Utility in Treating CNS Disorders such as Huntington's Disease.
J.Med.Chem., 57, 2014
|
|
4O0B
 | | Identification of novel HSP90/isoform selective inhibitors using structure-based drug design. Demonstration of potential utility in treating CNS disorders such as Huntington's disease | | Descriptor: | 8-cyclopentyl-6-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)-3,4-dihydroisoquinolin-1(2H)-one, Heat shock protein HSP 90-alpha | | Authors: | Zuccola, H.J, Ernst, J.T. | | Deposit date: | 2013-12-13 | | Release date: | 2014-04-09 | | Last modified: | 2024-02-28 | | Method: | X-RAY DIFFRACTION (1.93 Å) | | Cite: | Identification of Novel HSP90 alpha / beta Isoform Selective Inhibitors Using Structure-Based Drug Design. Demonstration of Potential Utility in Treating CNS Disorders such as Huntington's Disease.
J.Med.Chem., 57, 2014
|
|
4O05
 | | Identification of novel HSP90/isoform selective inhibitors using structure-based drug design. Demonstration of potential utility in treating CNS disorders such as Huntington's disease | | Descriptor: | 2,7,7-trimethyl-9-[1-oxo-8-(propan-2-ylamino)-1,2,3,4-tetrahydroisoquinolin-6-yl]-1,2,3,4,6,7,8,9-octahydro-5H-beta-carbolin-5-one, Heat shock protein HSP 90-alpha | | Authors: | Zuccola, H.J, Ernst, J.T. | | Deposit date: | 2013-12-13 | | Release date: | 2014-04-09 | | Last modified: | 2024-02-28 | | Method: | X-RAY DIFFRACTION (1.79 Å) | | Cite: | Identification of Novel HSP90 alpha / beta Isoform Selective Inhibitors Using Structure-Based Drug Design. Demonstration of Potential Utility in Treating CNS Disorders such as Huntington's Disease.
J.Med.Chem., 57, 2014
|
|
7S1W
 | | The AAVrh.10-glycan complex | | Descriptor: | Capsid protein VP1, beta-D-galactopyranose | | Authors: | Mietzsch, M, McKenna, R. | | Deposit date: | 2021-09-02 | | Release date: | 2021-09-22 | | Last modified: | 2024-06-05 | | Method: | ELECTRON MICROSCOPY (3.09 Å) | | Cite: | Structural Study of Aavrh.10 Receptor and Antibody Interactions.
J.Virol., 95, 2021
|
|
5THL
 | |
5THH
 | |
5UJJ
 | |
4O07
 | | Identification of novel HSP90/isoform selective inhibitors using structure-based drug design. Demonstration of potential utility in treating CNS disorders such as Huntington's disease | | Descriptor: | 2,7,7-trimethyl-9-[8-(2-methylpropyl)-1-oxo-1,2,3,4-tetrahydroisoquinolin-6-yl]-1,2,3,4,6,7,8,9-octahydro-5H-beta-carbolin-5-one, Heat shock protein HSP 90-alpha | | Authors: | Zuccola, H.J, Ernst, J.T. | | Deposit date: | 2013-12-13 | | Release date: | 2014-04-09 | | Last modified: | 2024-02-28 | | Method: | X-RAY DIFFRACTION (1.86 Å) | | Cite: | Identification of Novel HSP90 alpha / beta Isoform Selective Inhibitors Using Structure-Based Drug Design. Demonstration of Potential Utility in Treating CNS Disorders such as Huntington's Disease.
J.Med.Chem., 57, 2014
|
|
2K2J
 | | NMR solution structure of the split PH domain from Phospholipase C gamma 2 | | Descriptor: | 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase gamma-2 | | Authors: | Harris, R, Bunney, T.D, Katan, M, Driscoll, P.C. | | Deposit date: | 2008-04-02 | | Release date: | 2008-09-09 | | Last modified: | 2024-05-01 | | Method: | SOLUTION NMR | | Cite: | Rac Regulates Its Effector Phospholipase C{gamma}2 through Interaction with a Split Pleckstrin Homology Domain.
J.Biol.Chem., 283, 2008
|
|
2VKR
 | | 3Fe-4S, 4Fe-4S plus Zn Acidianus ambivalens ferredoxin | | Descriptor: | FE3-S4 CLUSTER, IRON/SULFUR CLUSTER, ZINC ION, ... | | Authors: | Frazao, C, Aragao, D, Coelho, R, Leal, S.S, Gomes, C.M, Teixeira, M, Carrondo, M.A. | | Deposit date: | 2007-12-23 | | Release date: | 2008-03-04 | | Last modified: | 2024-02-07 | | Method: | X-RAY DIFFRACTION (2.01 Å) | | Cite: | Crystallographic analysis of the intact metal centres [3Fe-4S](1+/0) and [4Fe-4S](2+/1+) in a Zn(2+) -containing ferredoxin.
FEBS Lett., 582, 2008
|
|
5K9G
 | | Crystal Structure of GTP Cyclohydrolase-IB with Tris | | Descriptor: | 1,2-ETHANEDIOL, 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL, FORMIC ACID, ... | | Authors: | Alvarez, J, Stec, B, Swairjo, M.A. | | Deposit date: | 2016-05-31 | | Release date: | 2016-09-07 | | Last modified: | 2023-10-25 | | Method: | X-RAY DIFFRACTION (1.9 Å) | | Cite: | Mechanism and catalytic strategy of the prokaryotic-specific GTP cyclohydrolase-IB.
Biochem.J., 474, 2017
|
|
5UJI
 | |
4O09
 | | Identification of novel HSP90 / isoform selective inhibitors using structure-based drug design. Demonstration of potential utility in treating CNS disorders such as Huntington s disease | | Descriptor: | 8-(2-methylpropyl)-6-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)-3,4-dihydroisoquinolin-1(2H)-one, Heat shock protein HSP 90-alpha | | Authors: | Zuccola, H.J, Ernst, J.T. | | Deposit date: | 2013-12-13 | | Release date: | 2014-04-09 | | Last modified: | 2024-02-28 | | Method: | X-RAY DIFFRACTION (1.96 Å) | | Cite: | Identification of Novel HSP90 alpha / beta Isoform Selective Inhibitors Using Structure-Based Drug Design. Demonstration of Potential Utility in Treating CNS Disorders such as Huntington's Disease.
J.Med.Chem., 57, 2014
|
|
